Risk Management Systems Should Be Constantly Evolving, FDA Official Says
FDA official Keisha Thomas emphasized at the RAPS Quality Conference that medical device risk management systems must be dynamic and continuously evolving to address firm-specific risks across all quality management system (QMS) areas. The FDA's new risk-based inspection program under the Quality Management System Regulation (QMSR) focuses on comprehensive compliance rather than conformity, highlighting common citations related to insufficient integration of risk management into decision-making and a decoupling of corrective and preventive actions. The agency also indicated that firms participating in the Medical Device Single Audit Program (MDSAP) may still face FDA inspections if risk signals warrant additional oversight.








